These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1306 related articles for article (PubMed ID: 29166236)

  • 21. Managing non-alcoholic fatty liver disease.
    Ngu JH; Goh GB; Poh Z; Soetikno R
    Singapore Med J; 2016 Jul; 57(7):368-71. PubMed ID: 27439352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current solutions for obesity-related liver disorders: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Raziel A; Sakran N; Szold A; Goitein D
    Isr Med Assoc J; 2015 Apr; 17(4):234-8. PubMed ID: 26040050
    [No Abstract]   [Full Text] [Related]  

  • 25. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N; Tsochatzis E
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
    Rinella ME; Neuschwander-Tetri BA; Siddiqui MS; Abdelmalek MF; Caldwell S; Barb D; Kleiner DE; Loomba R
    Hepatology; 2023 May; 77(5):1797-1835. PubMed ID: 36727674
    [No Abstract]   [Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
    Angulo P; Machado MV; Diehl AM
    Semin Liver Dis; 2015 May; 35(2):132-45. PubMed ID: 25974899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease progression: Divergent paths.
    DeWeerdt S
    Nature; 2017 Nov; 551(7681):. PubMed ID: 29168825
    [No Abstract]   [Full Text] [Related]  

  • 30. Paediatric non-alcoholic fatty liver disease: a practical overview for non-specialists.
    Mann JP; Goonetilleke R; McKiernan P
    Arch Dis Child; 2015 Jul; 100(7):673-7. PubMed ID: 25633064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating periostin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Papatheodorou A; Kokkoris P; Terpos E
    Endocrine; 2017 May; 56(2):438-441. PubMed ID: 27738886
    [No Abstract]   [Full Text] [Related]  

  • 32. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease.
    Goyal NP; Schwimmer JB
    Clin Liver Dis; 2016 May; 20(2):325-38. PubMed ID: 27063272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease in Pediatrics.
    Duncan M; Zong W; Biank VF; Hageman JR
    Pediatr Ann; 2016 Feb; 45(2):e54-8. PubMed ID: 26878184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Liver Biopsy Necessary in Patients With Nonalcoholic Fatty Liver Disease?
    Gavril RS; Mihalache L; Arhire L; Grosu C; Gherasim A; Nita O; Oprescu AC; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):503-7. PubMed ID: 30044567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which patients with nonalcoholic fatty liver disease should undergo liver biopsy?
    Lindenmeyer CC; McCullough AJ
    Cleve Clin J Med; 2017 Apr; 84(4):273-275. PubMed ID: 28388384
    [No Abstract]   [Full Text] [Related]  

  • 37. The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis.
    Buchman AL; Naini BV; Spilker B
    Semin Liver Dis; 2017 Feb; 37(1):33-44. PubMed ID: 28201847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis.
    Osayande AS; Kale N
    Am Fam Physician; 2017 Jun; 95(12):796-797. PubMed ID: 28671424
    [No Abstract]   [Full Text] [Related]  

  • 39. Female spontaneously diabetic Torii fatty rats develop nonalcoholic steatohepatitis-like hepatic lesions.
    Ishii Y; Motohashi Y; Muramatsu M; Katsuda Y; Miyajima K; Sasase T; Yamada T; Matsui T; Kume S; Ohta T
    World J Gastroenterol; 2015 Aug; 21(30):9067-78. PubMed ID: 26290633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists.
    Kleiner DE; Bedossa P
    Gastroenterology; 2015 Nov; 149(6):1305-8. PubMed ID: 26409177
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.